Nguyen Thong Ba, Lac Quan, Abdi Lovina, Banerjee Dipanjan, Deng Youping, Zhang Yiqiang
Department of Anatomy, Biochemistry and Physiology, Honolulu, HI, United States.
Center for Cardiovascular Research, Honolulu, HI, United States.
Front Cell Dev Biol. 2023 Jan 4;10:1071243. doi: 10.3389/fcell.2022.1071243. eCollection 2022.
investigation on human development, disease modeling, and drug discovery has been empowered by human induced pluripotent stem cell (hiPSC) technologies that form the foundation of precision medicine. Race and sex genetic backgrounds have become a major focus of many diseases modeling and drug response evaluation in the pharmaceutical industry. Here, we gathered data from major stem cell repositories to analyze the diversity with respect to ethnicity, sex, and disease types; and we also analyzed public datasets to unravel transcriptomics differences between samples of different ethnicities and sexes. We found a lack of diversity despite the large sample size of human induced pluripotent stem cells. In the ethnic comparison, the White group made up the majority of the banked hiPSCs. Similarly, for the organ/disease type and sex comparisons, the neural and male hiPSCs accounted for the majority of currently available hiPSCs. Bulk RNA-seq and single-cell transcriptomic analysis coupled with Machine Learning and Network Analysis revealed panels of gene features differently expressed in healthy hiPSCs and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) of different races and sexes. The data highlights the current ethnic and sex inequality in stem cell research and demonstrates the molecular biological diversity of hiPSCs and cardiomyocytes from different races and genders. We postulate that future efforts in stem cell biology, regenerative and precision medicine should be guided towards an inclusive, diverse repository reflecting the prevalence of diseases across racial and ethnic groups and the sexes, important for both common and rare disease modeling, drug screening, and cell therapeutics.
人类诱导多能干细胞(hiPSC)技术为人类发育、疾病建模和药物发现的研究提供了支持,这些技术构成了精准医学的基础。种族和性别遗传背景已成为制药行业许多疾病建模和药物反应评估的主要焦点。在这里,我们从主要的干细胞库收集数据,以分析种族、性别和疾病类型方面的多样性;我们还分析了公共数据集,以揭示不同种族和性别的样本之间的转录组学差异。我们发现,尽管人类诱导多能干细胞样本量很大,但仍缺乏多样性。在种族比较中,白人组在储存的hiPSC中占大多数。同样,在器官/疾病类型和性别比较中,神经和男性hiPSC在目前可用的hiPSC中占大多数。批量RNA测序和单细胞转录组分析,结合机器学习和网络分析,揭示了在不同种族和性别的健康hiPSC和人类诱导多能干细胞衍生的心肌细胞(hiPSC-CM)中差异表达的基因特征组。这些数据突出了目前干细胞研究中的种族和性别不平等,并展示了来自不同种族和性别的hiPSC和心肌细胞的分子生物学多样性。我们推测,干细胞生物学、再生医学和精准医学未来的工作应朝着一个包容性、多样化的库发展,该库反映了不同种族和民族以及不同性别中疾病的流行情况,这对常见和罕见疾病建模、药物筛选和细胞治疗都很重要。